Discovery of novel avermectins with unprecedented insecticidal activity

H. Mrozik, P. Eskola, B. O. Linn, A. Lusi, T. L. Shih, M. Tischler, F. S. Waksmunski, M. J. Wyvratt, N. J. Hilton, T. E. Anderson*, J. R. Babu, R. A. Dybas, F. A. Preiser and M. H. Fisher

Merck Sharp & Dohme Research Laboratories, Rahway (New Jersey 07065, USA) Received 3 October 1988; accepted 10 November 1988

Summary. A new class of insecticidal and antiparasitic agents, 4''-amino-4''-deoxy avermectins, has been developed by chemical modification of avermectin B_1 . The most effective of these compounds are 1500-fold more potent than avermectin B_1 (abamectin) against the beet armyworm Spodoptera exigua and show similar potency against other lepidopteran larvae. Key words. 4''-Amino-4''-deoxyavermectins; avermectin; insecticide; Lepidoptera.

The avermectins are a group of closely related macrocyclic lactones with exceedingly high activity against helminths and arthropods ¹.

Ivermectin (1), the 22,23-dihydro derivative of avermectin B_1 (2), is widely used as a systemic antiparasitic agent against endo and ectoparasites of animals 2 . It has also recently been found effective for the prevention of 'river blindness' in man caused by infection with the filarial worm *Onchocerca volvulus* 3 .

Avermectin B_1 (abamectin, **2**) is broadly effective against most important agricultural pests with LC_{90} s in the range of 0.02 ppm for mites. However, it is much less toxic to insects, especially lepidopteran larvae, where for example, a concentration of 6 ppm is required for LC_{90} level control of the southern armyworm *Spodoptera eridania*⁴.

An extensive program of chemical modification has been carried out in these laboratories to discover new avermectin derivatives with increased potency and spectrum of activity against armyworm species and other commercially important lepidopteran larvae.

As part of this program a series of 4"-amino avermectins was obtained by oxidation of the 4"-hydroxy group with the Swern reagent (oxalyl chloride, DMSO, NEt₃), after protection of other reactive hydroxy groups as O-t-butyl-dimethylsilyl ethers ⁵.

Reductive amination of the thus obtained 5-O-t-butyl-dimethylsilyl-4"-oxoavermectin B_1 (3) with NH₄OAc and NaCNBH₃ gave a mixture which was separated by preparative silicagel chromatography into the axial (epi)-amino derivative (4) as the major product, the equatorial amino derivative (5) and a small amount of 4"-epiavermectin B_1 (6). Deprotection gave the desired 4"-epiamino-4"-deoxyavermectin (7) 6 . N-alkylated derivatives were synthesized either by reductive amination using an alkylamine or by alkylation of 4"-amino-4"-deoxyavermectins.

The two epimeric 4''-amino-4''-deoxyavermectin B_1 derivatives had similar biological properties with the 4''-epiamino compound (7) being a somewhat more potent insecticide. Since the 4''-epiamino derivatives were also the major products of reductive amination they were selected for further

Compound	$R_{4^{''}eq}$	$R_{4''ax}$	R ₅	R ₂₆	$C_{22} - X - C_{23}$
1	НО	Н	Н	>80% C ₂ H ₅	-CH ₂ -CH ₂ -
2	НО	Н	Н	$<20\% \text{ CH}_3$ > 80% C ₂ H ₅	-CH = CH -
3	O		$Si(CH_3)_2 C(CH_3)_3$	<20% CH ₃ >80% C ₂ H ₅	-CH = CH -
4	Н	H_2N	$Si(CH_3)_2 C(CH_3)_3$	$<20\% \text{ CH}_3$ > 80% C ₂ H ₅	-CH = CH -
5	H_2N	Н	$Si(CH_3)_2 C(CH_3)_3$	$<20\% \text{ CH}_3$ >80% C ₂ H ₅	-CH = CH -
6	Н	НО	$Si(CH_3)_2 C(CH_3)_3$	$<20\% \text{ CH}_3$ >80% C ₂ H ₅	-CH = CH -
7	Н	H_2N	Н	$<20\% \text{ CH}_3 >80\% \text{ C}_2\text{H}_5$	-CH = CH -
8	Н	H ₃ CHN	Н	$<20\% \text{ CH}_3$ > 80% C_2H_5 $<20\% \text{ CH}_3$	-CH = CH -

Table 1. The biological activity of 4"-amino avermectin B₁ derivatives against neonate Spodoptera eridania larvae on sieva beans in a foliage spray bioassay. % Mortality after 96 hours

Compound	0.1 ppm	0.02 ppm	0.004 ppm
Avermectin B ₁ (abamectin) (2)	5	5	
4"-epiamino (7)	100	100	53
4"-epimethylamino (8)	100	100	51

Table 2. Activity after topical application to neonate larvae of S. eridania

Compound 0.1 μg/g	% Mortality		
4"-epiamino (7)	55		
4"-epimethylamino (8)	100		

study, details of which will be reported elsewhere. This report describes studies on the two most active members of the series shown in the figure.

Since the LC₉₀ for avermectin B₁ is 6 ppm, this represents a 300-400-fold improvement in insecticidal activity in this assay with the 4"-amino derivatives.

The activities of these two compounds, 4"-epiamino-4"-deoxyavermectin B₁ (7) and 4"-epimethylamino-4"-deoxyavermectin B₁ (8) were then compared by topical application with observation of mortality after 72 h. As can be seen in table 2 the 4"-epimethylamino compound (8) was considerably more active when applied topically.

Since contact activity can be an important attribute for an insecticide, the 4"-epimethylamino analog was selected for more detailed study.

In a diet incorporation assay 4"-epimethylamino-4"-deoxyavermectin B₁ (8) was approximately 1500-fold more toxic to Spodoptera exigua larvae than avermectin B_1 . The dose necessary to cause 90% mortality was 1972 ng/ml of diet for avermectin B₁ (2) compared to 1.067 ng/ml diet for 4"-epimethylamino-4"-deoxyavermectin B_1 (8)⁷. In a contact plus residue test comparing 4"-epimethylamino-4"deoxyavermectin B₁ applied at a rate of 0.012 kg/ha with methomyl at 1.008 kg/ha against S. exigua larvae, the acute toxicity of both treatments was similar but only 4"-epimethylamino-4"-deoxyavermectin B₁ treatment showed significantly less leaf consumption 14 days after application These data indicate that 4"-epimethylamino-4"-deoxyavermectin B₁ is one of the most potent insecticides yet discovered particularly for those lepidopteran larvae which are primarily foliage feeders. It is presently being studied against insects of several orders ^{8,9}.

- * Present address: Boyce Thompson Institute for Plant Research at Cor-
- nell University, Tower Road, Ithaca, N.Y. 14853-1801, USA. Albers-Schönberg, G., Arison, B. H., Chabala, J. C., Douglas, A. W., Eskola, P., Fisher, M. H., Lusi, A., Mrozik, H., Smith, J. L., and Tolman, R. L., J. Am. Chem. 103 (1981) 4216. 2 Campbell, W. C., Fisher, M. H., Stapley, E. O., Albers-Schönberg, G.,
- and Jacob, T. A., Science 221 (1983) 823.
- 3 Lariviere, M., Aziz, M., Weinmann, D., Ginoux, J., Gaxotte, P., Vingtain, P., Beauvais, B., Derouin, F., Schulz-Key, H., Basset, D., and Sarfati, C., Lancet 2 (1985) 174.
- 4 Putter, I., MacConnell, J. G., Preiser, F. A., Haidri, A. A., Ristich, S. S., and Dybas, R. A., Experientia 37 (1981) 963.
- Mrozik, H., Eskola, P., Fisher, M. H., Egerton, J. R., Cifelli, S., and Ostlind, D. A., J. med. Chem. 25 (1982) 658.
- 6 Mrozik, H., U.S. Patent 4,427,663 (1984).
- Trumble, J. T., Moar, W. J., Babu, J. R., and Dybas, R. A., J. Agric. Ent. 4 (1987) 21
- 8 Dybas, R. A., Hilton, N. J., Babu, J. R., Preiser, F. A., and Dolce, G. J., Novel Microbial Products for Medicine and Agriculture. Eds Demain, Hunter-Cevera, Rossmoore and Somkuti. Elsevier, Amsterdam (in press) 1988.
- 9 Dybas, R. A., and Babu, J. R., 1988 British Crop Protection Conference - Pests and Diseases (in press) 1988.

0014-4754/89/030315-02\$1.50 + 0.20/0© Birkhäuser Verlag Basel, 1989

Instructions to Authors

Experientia is a monthly journal for life sciences devoted to publishing articles which are interdisciplinary in character and which are of genera scientific interest. Considered for publication will be hitherto unpublished papers that fall within the following categories:

Reviews (one-man and multi-author reviews) Mini-reviews (1-2 printed pages)Research Articles (2-5 printed pages), published within 3 months of

Papers reporting on work that is preliminary in nature, or wherein animal experiments have been conducted without the appropriate anesthesia,

will not be accepted.

Manuscripts (including all tables and figures) must be submitted in *triplicate* and must be in *English*. *Title pages* should bear the author's name and address (placed directly below the title), a brief *abstract* (of approximately 50 words for short communications) mentioning new results only, and a listing of *key words*. *Footnotes* must be avoided. *Tables*, and then figures, are to follow the body of the text and should be marked with self-explanatory captions and be identified with the author's name. All data should be expressed in units conforming to the Système International (SI). Drawings are to be on heavy bond paper and marked clearly in black. Photographs should be supplied as glossy positive prints. Please note that we use two different systems for citing references. 1. For Review Articles, references should be arranged alphabetically and be numbered. Within the text, literature should be referred to by number and, where indicated, by author. The references should contain full journal article titles and the first as well as the last page of the article cited. 2. For Research Articles and Mini-reviews, an abbreviated bibliography is requested and references should be listed chronologically. Please consult a current issue of Experientia or inquire at the editorial office for details on form. Authors are requested to specify into which discipline their papers fall:

- 1. Anatomy, Physiology
- 2. Biochemistry and Biophysics Neurobiology Pharmacology
- 3. Endocrinology
- 4. Cellular Biology Molecular Biology Immunology
- 5. Genetics, Developmental Biology
- Ethology, Ecology Natural Product Chemistry

All incoming manuscripts are acknowledged immediately. Authors will be notified of the editorial board's publishing decision once their manuscripts have been evaluated by a minimum of two field experts. Fifty reprints of papers accepted for publication will be sent to authors free of charge; additional reprints may be ordered.

Manuscripts and all communications to the editors should be addressed

Experientia Birkhäuser Verlag P.O. Box 133 CH-4010 Basel/Switzerland Tel. 061 73 53 00